Five Pharmaceutical Names Lead MarketBeat's Watchlist for September 25
MarketBeat's stock screener identified Eli Lilly, Merck, Johnson & Johnson, Viking Therapeutics, and Gilead Sciences as pharmaceutical stocks with high recent dollar trading volume. The list includes large diversified drugmakers as well as Viking, a clinical-stage company focused on metabolic and endocrine therapies. Investors in the sector face risks tied to clinical trials, regulatory decisions, patent expirations, pricing pressure, and competition.
MarketBeat’s screener highlighted five drugmakers by recent dollar-based trading activity: Eli Lilly, Merck, Johnson & Johnson, Viking Therapeutics, and Gilead Sciences. Eli Lilly’s portfolio spans diabetes and obesity treatments, including Mounjaro and Zepbound. Merck and Johnson & Johnson offer broader health-care operations, while Gilead focuses on medicines for unmet needs, including infectious diseases.
Viking Therapeutics differs as a clinical-stage firm pursuing metabolic and endocrine therapies. Its lead candidate, VK2809, is in mid-stage testing for liver disease. The sector carries risks from trial outcomes, regulatory rulings, patent losses, pricing constraints, and competition.
The watchlist may shape investor attention toward these companies, potentially influencing share trading and capital access. Patients and caregivers could feel effects if pipeline successes or setbacks alter availability, pricing, or competition in diabetes, obesity, infectious disease, and liver conditions. Health systems and insurers may also watch approvals and patent expirations, since these can affect treatment options and costs. However, the list reflects recent trading activity, not clinical or regulatory outcomes.